PTPN11 and diabetes mellitus: Furthermore, monocytes from db/db mice (n = 6) and DM patients (n = 8) did not respond significantly towards PlGF-1 and this impaired responsiveness towards PlGF-1 could be restored completely by the use of SHP-2-inhibitor indicating clearly that therapeutic targeting of SHP-2 could reverse monocyte dysfunction (Fig. 5e,f).